Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

• Published in: JAMA oncology Vol. 7; no. 2; p. 271
• Main Authors: Kalinsky, Kevin, Hong, Fangxin, McCourt, Carolyn K, Sachdev, Jasgit C, Mitchell, Edith P, Zwiebel, James A, Doyle, L Austin, McShane, Lisa M, Li, Shuli, Gray, Robert J, Rubinstein, Larry V, Patton, David, Williams, Paul M, Hamilton, Stanley R, Conley, Barbara A, O'Dwyer, Peter J, Harris, Lyndsay N, Arteaga, Carlos L, Chen, Alice P, Flaherty, Keith T
• Format: Journal Article
• Language: English
• Published: United States 01.02.2021
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - pathology; Female; Humans; Middle Aged; National Cancer Institute (U.S.); Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; United States; United States

In the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, agents targeting genetic tumor abnormalities are administered to patients. In the NCI-MATCH subprotocol EAY131-Y trial, patients with an AKT1 E17K-mutated metastatic tumor received the pan-AKT inhibitor capivas...